- VistaGen Therapeutics Inc VTGN has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD).
- PH94B is an odorless, rapid-onset, investigational pherine nasal spray.
- PALISADE-1 is being conducted with approximately 200 subjects.
- Topline results from PALISADE-1 are anticipated in mid-2022.
- Price Action: VTGN shares are up 1.35% at $3.01 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
